SUNESIS PHARMACEUTICALS INC's ticker is SNSS and the CUSIP is 867328700. A total of 47 filers reported holding SUNESIS PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is 0.57 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2020 | $107,000 | -66.0% | 406,690 | -46.5% | 0.00% | – |
| Q1 2020 | $315,000 | -16.2% | 759,990 | -31.7% | 0.00% | – |
| Q4 2019 | $376,000 | -53.2% | 1,112,543 | -0.3% | 0.00% | – |
| Q3 2019 | $803,000 | -17.6% | 1,115,465 | -16.8% | 0.00% | – |
| Q2 2019 | $975,000 | -14.7% | 1,341,151 | +42.7% | 0.00% | – |
| Q1 2019 | $1,143,000 | +4472.0% | 939,958 | +1486.5% | 0.00% | – |
| Q4 2018 | $25,000 | -87.0% | 59,247 | -38.4% | 0.00% | – |
| Q3 2018 | $192,000 | -33.8% | 96,138 | -29.6% | 0.00% | – |
| Q2 2018 | $290,000 | +65.7% | 136,623 | +112.3% | 0.00% | – |
| Q1 2018 | $175,000 | +2.3% | 64,367 | +38.4% | 0.00% | – |
| Q4 2017 | $171,000 | -7.6% | 46,514 | -51.2% | 0.00% | – |
| Q3 2017 | $185,000 | +63.7% | 95,247 | +127.6% | 0.00% | – |
| Q2 2017 | $113,000 | +17.7% | 41,851 | +77.4% | 0.00% | – |
| Q1 2017 | $96,000 | +65.5% | 23,597 | +46.2% | 0.00% | – |
| Q4 2016 | $58,000 | +41.5% | 16,142 | +71.0% | 0.00% | – |
| Q3 2016 | $41,000 | – | 9,442 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aisling Capital Management LP | 7,600,000 | $9,234,000 | 7.03% |
| Samsara BioCapital, LLC | 3,750,000 | $4,556,000 | 3.58% |
| CAXTON CORP | 277,245 | $337,000 | 0.31% |
| BVF INC/IL | 2,287,860 | $2,780,000 | 0.31% |
| Eventide Asset Management | 5,965,455 | $7,248,000 | 0.25% |
| Telemetry Investments, L.L.C. | 197,564 | $240,000 | 0.12% |
| NEA Management Company, LLC | 1,298,274 | $1,584,000 | 0.08% |
| RP Management, LLC | 129,517 | $158,000 | 0.08% |
| Palo Alto Investors LP | 1,162,473 | $1,412,000 | 0.06% |
| Fosun International Ltd | 725,000 | $863,000 | 0.06% |